CMS Expands Medicare Coverage for Molecular Diagnostic Tests

The Centers for Medicare & Medicaid Services (CMS) is expanding Medicare coverage for genetic testing through the MolDX program administered by Palmetto GBA.

CMS announced two new local coverage determinations (LCDs) to cover diagnostic tests used to evaluate and manage care for patients suspected of having hereditary transthyretin amyloidosis:

• Genetic Testing for Heritable Thoracic Aortic Disease (L39933)
• Molecular Testing for Identification and Management of Hereditary Transthyretin Amyloidosis (L39935)

The LCDs will take effect Aug. 17 in 23 states.

Source:

https://www.cap.org/advocacy/latest-news-and-practice-data/july-8-2025